Regulatory filing by diagnostic company citing a Journal of Clinical Oncology paper — Natera, 2024-08-08
NateraNateraNASDAQ NTRA
Filings SEC · Quote Yahoo cited a paper published in the Journal of Clinical Oncology as a basis for its claims in a regulatory filing with the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated, in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a retrospective judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper like this in the press release
When a U.S. listed company has something to inform its shareholders, the form it files with the Securities and Exchange Commission is called 8-K. The item numbers in the document filed by Natera on 2024-08-08 were 2.02 Earnings announcement · 9.01 Financial statements · Attached documents. The company cited a paper published in Journal of Clinical Oncology in the press release attached to it. If the sentence citing the paper is translated verbatim, it reads as follows.
Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Res id ual Disease: Surveillance and Prognostic Implications. J Clin Oncol. 2024. doi : 10.1200/JCO.23.02054. 2.
What readers should first check is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which only read the abstract, cannot provide an answer to that.
The scope of the paper discussed in the abstract is limited to this.
The paper's title is Circulating Tumor DNA Assay Detects Merkel Cell Carcinoma Recurrence, Disease Progression, and Minimal Residual Disease: Surveillance and Prognostic Implications and it was published in Journal of Clinical Oncology on 2024-07-25. The authors are affiliated with University of Washington · Brigham and Women's Hospital · Harvard University · Dana-Farber Cancer Institute. The summary at the beginning of the paper is called abstract. This article only read up to that point. The paragraph was written by a person after filtering a draft generated by a machine through numerical comparison, and thus differs in quality from a full reading of the paper.
This is a prospective observational study examining whether recurrence of Merkel cell carcinoma, a skin cancer with frequent recurrence and no reliable tracking method, can be detected using fragments of tumor DNA in the blood. Plasma samples, clinical records, and imaging results from 319 patients were collected, and tests reflecting tumor information for each patient were used. Samples were divided into a discovery group and a validation group to assess sensitivity, specificity, and positive and negative predictive values. Since this is an observational study, the paper does not address whether survival improves by tracking with this test.
What the abstract does not answer remains in the full paper and its appendices. This article, which did not go beyond the abstract, leaves the gaps as they are. Readers should compare the two citations above to determine which sentence in the abstract corresponds to the citation provided by the company.
One month later, the stock price was within the middle half of the sample.
The remaining return after subtracting the portion that moves with the overall market is called excess return. The date is written as trading day, counting only the days the stock market is open. In calendar terms, 20 trading days are approximately one month. The excess return for the day of the regulatory filing and the following month are listed in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| Five trading days before the filing | +6.5% | The extent of movement before the filing |
| On the day of the filing | +5.6% | On the filing day or the first trading day thereafter |
| Accumulated over +1 to +5 trading days | +16.3% | One week |
| Cumulative +1~+20 trading days | +3.9% | One month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of +3.9% in this case is within the bottom 71% of the 142 samples and is within the lower half.
| Sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | This case |
|---|---|---|---|---|---|---|
| Excess return | −31.9% | −20.1% | −7.4% | +5.5% | +19.5% | +3.9% |
Half of the sample falls between the two central marks in the chart. One checks from the chart whether this case lies inside or outside. The sample collects cases where U.S. listed companies wrote papers in 8-K over the past ten years. The company itself is excluded from the sample. The numbers written here are past facts, not rules to apply to the next case.
There are four more cases where the same company wrote papers in 8-K, and they are placed together in the table below.
| Disclosure date | the journal of the paper | excess return for one month |
|---|---|---|
| 2021-11-04 | Clinical Journal of the American Society of Nephrology | −13.1% |
| 2022-11-08 | Transplantation | −12.1% |
| 2023-02-28 | Journal of Genetic Counseling | +18.2% |
| 2025-11-06 | New England Journal of Medicine | +18.7% |
after the filing, the company issued such documents
after the filing date, the company issued three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be identified by the number. The specific event is read in the original text of each link.
- 2024-11-12 8-K Item 2.02, 9.01 — Earnings announcement · Financial statements · Attached documents
- 2024-12-06 8-K Item 5.02 — Changes in Directors and Executive Officers
- 2025-01-13 8-K Item 2.02, 9.01 — Earnings Announcement · Financial Statements · Attached Documents
What This Article Does Not Answer
This article, which reads only abstracts, cannot answer what the paper re-examined, how, or to what extent. The number of times the paper cited by the company has been cited afterward can be verified again through the OpenAlexOpenAlex
Data source · Website citation count. The next thing to look at is whether the company's next 8-K filing cites the same paper again.
Term explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission when a listed company in the United States has something to inform its shareholders. The types are indicated by item numbers such as earnings, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company alone after removing the portion where the market as a whole rises or falls.
- Trading day
- A date counted only on days when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one calendar month.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position counted from the bottom is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary placed at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the method.